Skip to content
Screener

Corcept Therapeutics CORT Other Income (Expense)

Other Income (Expense) at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
-$36.27M-466%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
$12.53M-14.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$5M-37.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$4.04M-120%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
-$795K-1,793%

Other financials

Income statement

See full
Revenue$256.1M+31.7%
Gross profit$252.1M+32.0%
Operating income$41.3M+54.8%
Net income$43.0M+22.3%
EPS (diluted)$0.36+24.1%

Balance sheet

See full
Cash & equivalents$112.3M+9.3%
Total debt$9.4M+42.6%
Total equity$705.8M+11.0%
Total assets$888.7M+10.8%

Cash flow

See full
Operating cash flow$33.5M-23.7%
CapEx$2.5M+4,335%
Free cash flow$31.0M-29.3%

Valuation

See full
Market cap$11.67B+57.0%
Enterprise value$11.57B+57.7%
P/E211.5×+156×
P/S14.1×+3.7×

Profitability

See full
Gross margin98.3%-0.1pp
Operating margin0.8%-13.5pp
Net margin6.6%-12.0pp
FCF margin12.9%-12.3pp

Returns & leverage

See full
Return on equity8.2%-13.5pp
Debt / equity0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:09 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-050613
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Selling, general and administrative156,896103,851302,252194,511
Total operating expenses214,847167,755429,351321,553
Income (loss) from operations41,30026,675(8,301)30,091
Interest and other income4,6315,0179,51711,219
Income before income taxes45,93131,6921,21641,310
Income tax (expense) benefit(2,944)3,45710,01014,386
Net income42,98735,14911,22655,696
Net income attributable to common stockholders42,14134,61111,01754,918

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Corcept Therapeutics's other income (expense)?
Corcept Therapeutics (CORT) reported other income (expense) of $4.63M in Q2 2026.
How has Corcept Therapeutics's other income (expense) changed year-over-year?
Corcept Therapeutics's other income (expense) decreased by 7.7% year-over-year, from $5.02M to $4.63M.
What is the long-term trend for Corcept Therapeutics's other income (expense)?
Over 4 years (2021 to 2025), Corcept Therapeutics's other income (expense) has grown at a 153.0% compound annual growth rate (CAGR), from $529K to $21.67M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.

Ask your AI about Corcept Therapeutics's other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude